In murine models of either CRC or Lewis lung cancer (LLC), blocking EZH2 with GSK126 in immunocompetent mice impaired anti-tumor immunity by boosting systemic MDSCs expansion and accumulation in TME. Here, EZH2 is linked to neoplasm.